Olsalazine

Olsalazine
Names
Trade namesDipentum
Other namesOlsalazine sodium
Clinical data
Drug class5-ASA derivative[1]
Main usesUlcerative colitis, Crohn’s disease[1][2]
Side effectsNumbess, fast heart beat[3]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: C[4]
  • US: C (Risk not ruled out)[4]
    Routes of
    use    		By mouth
    Typical dose500mg BID[3]
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa601088
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only
    Pharmacokinetics
    Protein binding99%
    Elimination half-life0.9 hours
    Chemical and physical data
    FormulaC14H10N2O6
    Molar mass302.242 g·mol−1
    3D model (JSmol)
    SMILES
    • O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
    InChI
    • InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ checkY
    • Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N checkY

    Olsalazine, sold under the brand name Dipentum among others, is a medication used to treat ulcerative colitis and Crohn’s disease.[1][2] It is used in people who cannot take sulfasalazine.[1] It is taken by mouth in the form of tablet or capsule.[3] If needed, contents of the capsule can be sprinkled on food.[3]

    Side effects are uncommon but include numbess and a fast heart beat.[3] Other side effects may include diarrhea, nausea, heartburn, tiredness, and headache.[1] Caution is advised in kidney problems.[3] It is broken down into mesalazine (5-ASA) in the colon by which it acts.[2] 5-ASA than inhibits cyclooxygenase and lipoxygenase thereby reducing prostoglandin and leukotriene production.[1]

    Olsalazine was approved for medical use in the United States in 1990.[1] It is available as a generic medication.[3] In the United Kingdom a months supply costs the NHS around £150 as of 2021.[3] In the United States this amount costs about 1,600 USD.[5]

    Medical uses

    It is used to treat ulcerative colitis and Crohn’s disease.[1][2]

    Dose

    In ulcerative colitis, a typical dose is 500mg twice daily after food.[3] Doses up to 3 grams per day; however, may be used.[6]


    It is taken by mouth in the form of tablet or capsule.[3] If needed, the contents of the capsule can be sprinkled on food.[3]

    History

    Olsalazine gained Food and Drug Administration (FDA) approval in 1990.[1]

    Society and culture

    Supply

    The drug is supplied by UCB Pharma.

    Cost

    In the UK, a months supply costs the NHS around £144 for the capsule form and £160 for the tablet.[3]

    Research

    In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[7]

    References

    1. 1 2 3 4 5 6 7 8 9 "Olsalazine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 7 November 2021.
    2. 1 2 3 4 "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 12 January 2021. Retrieved 9 January 2021.
    3. 1 2 3 4 5 6 7 8 9 10 11 12 "1. Gastro-intestinal system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 47. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
    4. 1 2 "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 18 January 2021. Retrieved 9 October 2020.
    5. ↑ "Olsalazine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 7 November 2021.
    6. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 47. ISBN 978-0857114105.
    7. ↑ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Archived from the original on 25 October 2021. Retrieved 16 January 2021.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.